Polycythemia clinical trials
The registry lists 183 studies for Polycythemia across more than 10 countries. 27 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-08-21.
Status
- Completed
- 107
- Terminated
- 24
- Recruiting
- 23
- Status unknown
- 14
- Withdrawn
- 8
- Not yet recruiting
- 4
Phase
- Phase 2
- 68
- Phase 1
- 41
- Phase 3
- 25
- Phase 4
- 4
- Early Phase 1
- 2
Where
- United States
- 104
- Italy
- 37
- France
- 35
- Germany
- 30
- Canada
- 28
- United Kingdom
- 25
Who runs them
Novartis Pharmaceuticals (14) · Sierra Oncology LLC - a GSK company (9) · National Cancer Institute (NCI) (8) · Incyte Corporation (6) · M.D. Anderson Cancer Center (6) · John Mascarenhas (5) · Fred Hutchinson Cancer Center (5) · Ronald Hoffman (5)
Studies
Recruiting first, then most recently updated. Showing 50 of 183 — search for more.
- The Effect Of Lisinopril On PolycythemiaRecruitingNCT07594535Phase 41 country
- Safety and Tolerability of ZE74-0282 in Healthy VolunteersRecruitingNCT07527221Phase 11 country
- Molecular Biology of Polycythemia and ThrombocytosisRecruitingNCT007225271 country
- 129Xe MRI CardiopulmonaryRecruitingNCT06038630Phase 21 country
- Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia VeraNot yet recruitingNCT07341048Not applicable1 country
- Blood Viscosity in Polycythemia PatientsRecruitingNCT064210251 country
- CPAP Effect on the Polycythemia in Patients With Obstructive Sleep ApneaRecruitingNCT06089603Phase 41 country
- Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisRecruitingNCT06770842Phase 21 country
- Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family HistoryNot yet recruitingNCT06923670Not applicable
- A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraRecruitingNCT06752746Phase 11 country
- POlycythemia, Proteins and ErYthropoiesisRecruitingNCT069051061 country
- EVAluation of Erythrocytosis PRospEctive Cohort STudyNot yet recruitingNCT067858701 country
- Efficacy and Safety of Peginterferon in ET and PV.RecruitingNCT06734637Not applicable1 country
- Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia VeraRecruitingNCT065164061 country
- Effect of Phlebotomy on Heartrate in Polycythemia PatientsRecruitingNCT053961701 country
- Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET PatientsRecruitingNCT04655092Phase 31 country
- A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With MyelofibrosisRecruitingNCT060738471 country
- Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT027602381 country
- Myeloproliferative Neoplastic Diseases Observatory From BrestRecruitingNCT028972971 country
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVRecruitingNCT05870475Phase 21 country
- Real-world Ruxolitinib Experience in PVNot yet recruitingNCT06251102
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 11 country
- Real World Evidence of Fedratinib Effectiveness in MFRecruitingNCT058839041 country
- Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis.RecruitingNCT059930651 country
- Asian Myeloproliferative Neoplasm (MPN) RegistryRecruitingNCT058827731 country
- KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentRecruitingNCT03662126Phase 2/328 countries
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisRecruitingNCT04878003Phase 29 countries
- A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentActive, not recruitingNCT04576156Phase 326 countries
- CO-Rebreathing in Comparison to Isotopic Red Cell Volume Determination in the Diagnosis of Primitive and Secondary PolycythemiaCompletedNCT03008642Not applicable1 country
- A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PVActive, not recruitingNCT05481151Phase 32 countries
- Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With MyelofibrosisTerminatedNCT04854096Phase 29 countries
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 11 country
- Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with ErythrocytosisCompletedNCT05487794Not applicable1 country
- Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCompletedNCT01420783Phase 29 countries
- Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedNCT01692366Phase 21 country
- A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedNCT03755518Phase 32 countries
- A Study to Evaluate P1101 in Japanese PV PatientsCompletedNCT06002490Phase 31 country
- The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PVCompletedNCT03003325Phase 21 country
- Clinical and Laboratory Characteristics of Polycythemia VeraCompletedNCT061341021 country
- Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsCompletedNCT04243122Phase 21 country
- A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia VeraCompletedNCT058534451 country
- Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative NeoplasmsCompletedNCT063715731 country
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 11 country
- PTG-300 in Patients With Polycythemia Vera and Elevated HematocritCompletedNCT04767802Phase 22 countries
- HIGH Altitude CArdiovascular REsearch Latin America Population StudyCompletedNCT047512921 country
- Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)CompletedNCT03136185Phase 1/25 countries
- CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT03972943Early Phase 11 country
- A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedNCT04173494Phase 322 countries
- Ruxolitinib Adherence in Myelofibrosis and Polycythemia VeraCompletedNCT060783191 country
- A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With MyelofibrosisCompletedNCT050440261 country